This prospective observational study aims to describe the effectiveness of MC on pain, epilepsy, sleep and /or anxiety/depression in a cohorts of patients authorized to use MC, using pre-defined, validated self assessment scales.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in pain intensity from baseline to week 24 post-authorization of MC: Measured using the numerical rating scale (NRS).
Timeframe: Baseline, 6, 12, 18 (if applicable) and 24 weeks
Change in pain interference from baseline to week 24 post-authorization of MC: Measured using the Patient-Reported Outcomes Measurement Information System (PROMIS)-Pain Interference short form 6a.
Timeframe: Baseline, 6, 12, 18 (if applicable) and 24 weeks
Sleep: Change in the Pittsburgh Sleep Quality Index (PSQI) from baseline to week 24 post-authorization of MC
Timeframe: Baseline, 6, 12, 18 (if applicable) and 24 weeks
Anxiety: Change in the symptoms from baseline to week 24 post-authorization of MC; Measured using Generalized Anxiety Disorder 7-item scale (GAD-7).
Timeframe: Baseline, 6, 12, 18 (if applicable) and 24 weeks
Depression: Change in the symptoms from baseline to week 24 post-authorization of MC. Measured by Patient Health Questionnaire 9 item scale (PHQ-9).
Timeframe: Baseline, 6, 12, 18 (if applicable) and 24 weeks
Change in quality of life from baseline to Week 24: Measured using EuroQuol-5D-3-level health questionnaires(EQ-5D-3L) assessment scale.
Timeframe: Baseline, 6, 12, 18 (if applicable) and 24 weeks
Epilepsy: change in seizure frequency for multiple different seizure types from baseline to Week 24
Timeframe: Baseline, 6, 12, 18 and 24 weeks